Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on immunology and inflammation therapeutics that accessed public markets through a SPAC transaction during the active 2021–2022 de-SPAC cycle. The company filed an amended quarterly report on Form 10-Q/A with the Securities and Exchange Commission on April 25, 2022, a routine amendment reflecting its standing as a post-merger reporting issuer. Zura Bio operates in the biotechnology and life sciences sector, with its pipeline centered on autoimmune and inflammatory disease indications. For full sponsor details, IPO year, and deal history on ZURA, sign up for complete data access at SpacDesk.